Trazpiroben (developmental code name TAK-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis. It acts as a peripherally selective dopamine D<sub>2</sub> and D<sub>3</sub> receptor antagonist. The drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective D<sub>2</sub> receptor antagonists like domperidone. Clinical development of trazpiroben was discontinued before April 2022. Trazpiroben was originated by Altos Therapeutics and was under development by Takeda Oncology.